You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameUstekinumabProduct NameSTELARA®Therapeutic AreaSkin and Connective Tissue DiseasesEnrollment312% Female52.6%% White98.4%
Product ClassAntipsoriaticsSponsor Protocol NumberCNTO1275PSA3002 /// PSUMMIT IIData PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)49
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2023-5145 : Improving efficiency of immune-mediated inflammatory disease trials through better design and analysis
- 2019-4067 : Evidence-generation for biologics in pediatric studies
- 2017-1746 : Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity
- 2017-1456 : The efficacy of biologic medications in improving depressive symptoms in patients with PsA ? Patient-level meta-analysis
- 2016-0897 : A systematic review and economic evaluation of certolizumab pegol and secukinumab for treating active psoriatic arthritis
- 2015-0560 : Construct and Content Validity of Instruments Used in Clinical Trials of Psoriatic Arthritis
- 2015-0339 : Impact of the dose of immunomodulators on pharmacokinetics of biologics: Patient level meta-analysis of randomized controlled trials